As expected, in the current study, CD36 peptide treatment did not affect obesity induced TSP1 expression in AT (Supplemental Fig. 3) but antagonized TSP1’s functions and reduced macrophage accumulation and proinflammatory activation in AT, resulting in reduced AT inflammation. Here, CD36 is linked to obesity due to melanocortin 4 receptor deficiency.